1,-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (methyl CCNU) and adriamycin combination therapy.
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy; D003510:Cyclohexanes; D003630:Daunorubicin / Q000627:therapeutic use; D004064:Digestive System / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010307:Parotid Neoplasms / Q000188:drug therapy; D013280:Stomatitis / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014786:Vision Disorders / Q000139:chemically induced
D003510:Cyclohexanes; D009607:Nitrosourea Compounds; D004317:Doxorubicin; D003630:Daunorubicin